“We're obviously very pleased to have received funding from the Bill & Melinda Gates Foundation, and we're even more excited about the prospects of this project. Using our BPU™ Platform to bring novel and feasible diagnosis capabilities to developing countries was a major driver as to why we started Cardea in the first place. Developing an electronic nose with the potential to diagnose diseases like COVID, malaria, cancer, and so on, is literally a dream come true!” states Michael Heltzen, CEO at Cardea Bio.
Chief Business Officer at Cardea, Rob Lozuk, adds, "We're extremely excited about how this project aligns perfectly with our commitment to positively impact a broad set of healthcare conditions, such as infectious diseases, environmental, and even oncology. By leveraging the foundation's innovations and presence across the globe, this uniquely positions us to validate the potential capabilities of the BPU in bringing healthcare to all corners of our civilization and ultimately allowing people across the world to live healthy and productive lives."
A successful completion of this project will provide validation that the Cardea BPU™ Platform has the potential to meet the needs of a large variety of engineered OR-enabled products for sensing applications in clinical health, environmental monitoring, agriculture, and biosecurity to name a few. Cardea would then focus on developing a point-of-care [POC] testing device that can rapidly screen for common infectious diseases in developing countries.
The benefits of having a single platform capable of a wide range of detection and diagnostic applications enables a drastic reduction in development time and cost. Ultimately this is a benefit to developing countries by deploying a single instrument with application specific tests in a rapid and cost-effective manner, yielding the highest impact in critically underserved communities.

Latest releases

2. May 2023
Paragraf acquires Cardea Bio to extend graphene electronics industry leadership
In a first for the graphene electronics industry, leading integrated device manufacturer Paragraf is acquiring graphene biosensor market pioneer Cardea Bio to accelerate the mass production of a new generation of...
19. April 2023
Dr. Kiana Aran’s CRISPR-chip selected for national German exhibition on novel genetic research
San Diego, CA -- April 19, 2023 – The ongoing exhibition ‘Of Genes and Human Beings’ at the national German DHMD museum in Dresden, highlights multiple technological advances in the genetic field over the last century...
4. April 2023
Dr. Kiana Aran makes Inc.’s 2023 Female Founders list
Inc. today announced its sixth annual Female Founders list, honoring a bold group of 200 women whose innovations and ideas are shaping the world into a better place.
10. January 2023